NFL Biosciences SAS - Asset Resilience Ratio

Latest as of June 2025: 4.52%

NFL Biosciences SAS (ALNFL) has an Asset Resilience Ratio of 4.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NFL Biosciences SAS short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€200.00K

≈ $233.82K USD Cash + Short-term Investments

Total Assets

€4.42 Million

≈ $5.17 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how NFL Biosciences SAS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ALNFL current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down NFL Biosciences SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ALNFL liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€200.00K	4.52%
Total Liquid Assets	€200.00K	4.52%

Asset Resilience Insights

Limited Liquidity: NFL Biosciences SAS maintains only 4.52% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

NFL Biosciences SAS Industry Peers by Asset Resilience Ratio

Compare NFL Biosciences SAS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for NFL Biosciences SAS (2021–2024)

The table below shows the annual Asset Resilience Ratio data for NFL Biosciences SAS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	5.54%	€200.00K ≈ $233.82K	€3.61 Million ≈ $4.22 Million	+0.72pp
2023-12-31	4.82%	€191.44K ≈ $223.82K	€3.97 Million ≈ $4.64 Million	-1.89pp
2022-12-31	6.71%	€160.85K ≈ $188.06K	€2.40 Million ≈ $2.80 Million	-2.26pp
2021-12-31	8.97%	€330.58K ≈ $386.48K	€3.69 Million ≈ $4.31 Million	--

pp = percentage points

About NFL Biosciences SAS

PA:ALNFL France Biotechnology

Market Cap

$10.90 Million

€9.33 Million EUR

Market Cap Rank

#26944 Global

#458 in France

Share Price

€0.74

Change (1 day)

+0.68%

52-Week Range

€0.73 - €1.65

All Time High

€4.75